You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
An Australian research team at the National Health and Medical Research Council Clinical Trials Centre at the University of Sydney tracked 9,795 type 2s, ages 50 to 75, over a five-year period. Half took 200 mg of fenofibrate daily, while the other half took a placebo.
At the end of the study, the risk of a first amputation among patients taking fenofibrate was 36 percent lower than among those taking the placebo. Researchers also noted that fenofibrate takers had a 47 percent lower risk of amputations below the ankle of feet that did not have large-vessel disease.
(Large vessel disease is caused by atherosclerosis of large arteries, usually the result of cardiovascular disease, as opposed to the microvascular disease commonly found in people with type 2.)
The beneficial aspects of fenofibrate consumption seemed to emerge after 1.5 years of continuous use. However, despite the notably encouraging reduction in the risk for below-the-ankle amputations, taking fenofibrate produced no reduction in the risk for above-the-ankle amputations.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.